Global Nanoparticle-Mediated Delivery Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Nanoparticle-Mediated Delivery Market Research Report 2024
Nanoparticle drug delivery systems are engineered technologies that use nanoparticles for the targeted delivery and controlled release of therapeutic agents. The modern form of a drug delivery system should minimize side-effects and reduce both dosage and dosage frequency. Recently, nanoparticles have aroused attention due to their potential application for effective drug delivery.
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
According to MRAResearch’s new survey, global Nanoparticle-Mediated Delivery market is projected to reach US$ 5927.2 million in 2033, increasing from US$ 4571.7 million in 2022, with the CAGR of 3.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanoparticle-Mediated Delivery market research.
Global Nanoparticle Drug Delivery Systems key players include Gilead Sciences, CSPC, Pacira, Alnylam, etc. Global top four manufacturers hold a share about 37%.
Asia-Pacific is the largest market, with a share about 37%, followed by Europe, and North America, both have a share over 56 percent.
In terms of product, Liposomes Drugs is the largest segment, with a share over 92%. And in terms of application, the largest application is Retail Pharmacy, followed by Hospital, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Nanoparticle-Mediated Delivery market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
AbbVie
BlueWillow Biologics
NovaSOL
Camurus
Ceramisphere
Celgene, CytImmune
Cristal Therapeutics
EnColl
Lena Nanoceutics Ltd.
EyePoint Pharmaceuticals
Nanobiotix
NanoCarrier
Nanospectra
NanOlogy
Selecta Biosciences
Parvus Therapeutics
Starpharma
Tarveda Therapeutics
Segment by Type
Biological Origin
Non-Biological Origin
Drug Delivery
Gene Delivery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nanoparticle-Mediated Delivery report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
In this report, we only study liposomal/lipid nanoparticle drug delivery system.
LNPs became more widely known in late 2020, as some COVID-19 vaccines that use RNA vaccine technology coat the fragile mRNA strands with PEGylated lipid nanoparticles as their delivery vehicle (including both the Moderna and the Pfizer–BioNTech COVID-19 vaccines).
In this report, the COVID-19 vaccines with lipid nanoparticles technologies are not covered. The COVID-19 vaccines launch on the end of 2020. We expect revenue for COVID-19 vaccines with lipid nanoparticles technologies in 2021 to be approximately 37 billion USD.
According to MRAResearch’s new survey, global Nanoparticle-Mediated Delivery market is projected to reach US$ 5927.2 million in 2033, increasing from US$ 4571.7 million in 2022, with the CAGR of 3.7% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nanoparticle-Mediated Delivery market research.
Global Nanoparticle Drug Delivery Systems key players include Gilead Sciences, CSPC, Pacira, Alnylam, etc. Global top four manufacturers hold a share about 37%.
Asia-Pacific is the largest market, with a share about 37%, followed by Europe, and North America, both have a share over 56 percent.
In terms of product, Liposomes Drugs is the largest segment, with a share over 92%. And in terms of application, the largest application is Retail Pharmacy, followed by Hospital, etc.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Nanoparticle-Mediated Delivery market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
AbbVie
BlueWillow Biologics
NovaSOL
Camurus
Ceramisphere
Celgene, CytImmune
Cristal Therapeutics
EnColl
Lena Nanoceutics Ltd.
EyePoint Pharmaceuticals
Nanobiotix
NanoCarrier
Nanospectra
NanOlogy
Selecta Biosciences
Parvus Therapeutics
Starpharma
Tarveda Therapeutics
Segment by Type
Biological Origin
Non-Biological Origin
Segment by Application
Drug Delivery
Gene Delivery
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nanoparticle-Mediated Delivery report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices